MANKIND PHARMA SHARES

Through the stake sale, Canada Pension Plan took home about Rs 256 crore. At the end of March quarter, it held 1.47% equity in the company. In separate deals, Capital group affiliate Hema CIPEF has sold 0.46% stake in Mankind Pharma for Rs 2,082 api...

Shares of Mankind Pharma surged 4% to Rs 2,187.85, and Delhivery rose 2% to Rs 403.65 on the BSE following stake sales via block deals. Hema CIPEF (I), an affiliate of Capital Group, likely sold 0.9% of Mankind Pharma. Canada Pension Plan Investment...

Sensex and Nifty hit records. Delta Corp's Q1 profit dips 34% to Rs 40.48 crore from Rs 61.43 crore last year. Paytm's One97 Communications faces labor notice. Bandhan Bank staff seek legal aid. JSW Steel updates production. Delhivery's equity sold ...

Capital Group held a 2.22% stake in the company as on March 31, 2024. In December last year, Capital Group divested a 3.14% stake in Mankind Pharma.

Hema CIPEF is selling 37 lakh shares (0.9% of its total equity) at a discounted price of Rs 2,061 per share, 2% below the current market value. As of the end of March, Hema CIPEF, a fund mostly owned by the company's promoters, held a 2.22% stake in...

Motilal Oswal initiated coverage on Mankind Pharma with a 'buy' call and target price of Rs 2,650. The company's disruptive strategy in establishing its DF business has made it an industry leader in prescriptions.

Top brokerage firms like Motilal Oswal, Jefferies, and Morgan Stanley have issued buy ratings and targets for Mankind Pharma, Nykaa, Tata Consumer, and Varun Beverages.

​According to data from stockedge.com, on June 10th, six stocks classified as large-cap appeared in the RSI Trending Up scan.

The week was an eventful one. Besides the general election results, D-Street saw some prominent block deals which included over three dozen companies from large, mid and smallcap segments. Shares worth Rs 7,640 crore were traded on screen, which inc...

In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sen...

Mankind Pharma, Dr Reddy's Laboratories, and Torrent Pharma are interested in acquiring JB Chemicals & Pharmaceuticals from KKR. KKR's investment arm, TAU Investment, owns 53.78% in JB Chemicals, worth Rs 14,020 crore. The company's revenue doubled ...

India's pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which...

Sanjiv Bhasin says Mankind has been a revelation purely on the back of some of the launches which have been well accepted and their domestic business has actually been way ahead of most of the peers. There is margin on the upside given that it is en...

HDFC Life announced its highest-ever bonus of Rs 3,722 crore on participating plans. This bonus will benefit over 22.23 lakh policyholders.

Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.

Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its board approved the raising of funds worth Rs 7,500 crore via the issuance of equity shares. For the full financ...

Benchmark equities surged for the third consecutive day on Tuesday. PFC, Mankind Pharma, Patanjali Foods, Bharti Airtel, Siemens, and Cipla are in focus for news developments and quarterly results. RVNL, Dixon, and Titagarh will also announce their ...

Paytm will be a high conviction exclusion, causing outflows of $77 million from India, the domestic brokerages' note said. Paytm's exclusion comes after a nearly 40% correction in the share price following RBI's ban on its Paytm Payments Bank. Meanw...

PE firm ChrysCapital's affiliate entity Beige Ltd was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares of Mankind Pharma at a price range of Rs 2,103.21 to Rs 2,214 per share.